Goldman Sachs analyst Adam Hotchkiss expressed expectations on Vertex, Inc. (NASDAQ:VERX) ahead of its first Investor Day as a public company on March 19. The analyst reiterated the Buy rating ...

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Vertex. The chart below shows the ...

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Vertex. The chart below shows the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Explore Vertex Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VRTX. Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

Vertex has established itself as a frontrunner in the indirect tax automation space, serving over 4,800 customers, including more than 60% of the Fortune 500. The company’s solutions are utilized in ...

Vertex, Inc. engages in the provision of tax compliance software solutions. The firm offers comprehensive solutions that automate end-to-end indirect tax processes for enterprises and mid-market ...